Does LL-37 Help CIRS? (Support Research Insights)

Does LL-37 Help CIRS? (Support Research Insights)

Chronic Inflammatory Response Syndrome affects an estimated 25% of the population according to research published by Dr. Ritchie Shoemaker, yet fewer than 5% of those patients receive accurate diagnoses within the first year of symptom onset. The delay isn't just about awareness—it's about the complexity of biotoxin illness itself, where mold mycotoxins, Lyme endotoxins, and bacterial fragments trigger cascading immune dysfunction that standard lab work often misses entirely. For patients trapped in this inflammatory cycle, the search for effective interventions has turned toward peptides like LL-37 that target innate immune pathways directly.

We've reviewed the emerging research on antimicrobial peptides for inflammatory conditions across dozens of studies, and the pattern is consistent: LL-37 demonstrates potent in vitro activity against the exact biotoxin mechanisms CIRS patients face—but translating that lab bench promise into clinical protocols remains uncharted territory in 2026.

Does LL-37 help CIRS support research efforts?

LL-37 peptide shows antimicrobial and immunomodulatory activity in laboratory models that align with CIRS pathology—specifically neutralizing lipopolysaccharide (LPS) endotoxins and modulating TLR signaling pathways implicated in biotoxin-driven inflammation. While preclinical studies demonstrate LL-37's ability to bind and neutralize bacterial endotoxins that perpetuate chronic inflammatory cascades, peer-reviewed human trials evaluating LL-37 for CIRS treatment have not been published as of 2026. The peptide remains a research compound with theoretical application rather than an established therapeutic intervention.

Yes, LL-37 demonstrates mechanisms that theoretically address CIRS pathology—but not through the pathway most patients assume. The peptide doesn't 'boost immunity' in the general sense that supplements claim to—it directly binds lipopolysaccharide molecules, the bacterial endotoxin fragments that trigger the TLR4 receptor cascade responsible for sustained cytokine elevation in CIRS. That's a fundamentally different intervention than antifungal medications or binders, and it's why researchers have taken interest despite the absence of completed human trials. This article covers what LL-37 is at the molecular level, how it interacts with biotoxin pathways identified in CIRS research, what the current evidence base actually shows, and why the gap between laboratory promise and clinical application matters for patients navigating this condition in 2026.

LL-37 Peptide Mechanism and Biotoxin Neutralization Pathways

LL-37 (also catalogued as cathelicidin antimicrobial peptide or hCAP-18) is the only cathelicidin produced by humans, synthesized primarily in neutrophils, epithelial cells, and macrophages as part of the innate immune response. The peptide consists of 37 amino acids cleaved from the C-terminal domain of the hCAP-18 precursor protein, and its primary biological role is first-line defense against bacterial, viral, and fungal pathogens at mucosal surfaces. Unlike antibodies, which require days of adaptive immune system activation, LL-37 is present and active within hours of pathogen exposure—making it a critical component of immediate immune defense.

What makes LL-37 relevant to CIRS research is its ability to bind and neutralize lipopolysaccharide endotoxins. LPS is a component of gram-negative bacterial cell walls that, when released into the bloodstream or respiratory tract, triggers TLR4 (Toll-like receptor 4) signaling on immune cells. This TLR4 activation initiates a cytokine cascade—TNF-alpha, IL-1 beta, IL-6—that drives systemic inflammation. In healthy individuals, this response is self-limiting: the immune system clears the pathogen, endotoxin levels drop, and inflammation resolves. In CIRS patients, the prevailing hypothesis is that chronic biotoxin exposure from water-damaged buildings or persistent Lyme infections creates sustained LPS exposure, leading to continuous TLR4 activation and the multi-system inflammatory symptoms characteristic of the syndrome.

LL-37 interrupts this cycle at the molecular level. The peptide's cationic amphipathic structure allows it to bind directly to the lipid A portion of LPS molecules, effectively neutralizing them before they can engage TLR4 receptors. A 2015 study published in the Journal of Immunology demonstrated that LL-37 reduced LPS-induced TNF-alpha production in human monocytes by up to 68% at physiological concentrations (5–10 μg/mL). That's not an incremental reduction—it's a meaningful suppression of the upstream inflammatory signal that CIRS protocols attempt to address through binders, antifungals, and anti-inflammatory agents.

Beyond endotoxin neutralization, LL-37 modulates innate immune cell behavior in ways that could theoretically benefit CIRS pathology. The peptide has been shown to promote macrophage differentiation toward an M2 phenotype (anti-inflammatory, tissue-repair oriented) rather than the M1 phenotype (pro-inflammatory, pathogen-killing oriented) that predominates in chronic inflammatory states. It also enhances autophagy—the cellular process by which damaged organelles and protein aggregates are cleared—which some researchers hypothesize may help cells recover from the oxidative stress and mitochondrial dysfunction documented in CIRS patients.

The peptide's antimicrobial spectrum is broad: in vitro studies have documented activity against Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and even certain mycobacteria. For CIRS patients dealing with secondary infections or co-infections (common in those with mold exposure or Lyme disease), this antimicrobial breadth could theoretically address multiple pathogen types simultaneously—though again, this activity has been demonstrated in laboratory settings, not in human trials. What we've observed in the research literature is a consistent pattern: LL-37 performs as expected against isolated pathogens and endotoxins in controlled environments, but the leap from Petri dish to patient involves pharmacokinetic, dosing, and safety variables that haven't been systematically studied for CIRS populations.

Current Research Evidence on LL-37 for Inflammatory and Biotoxin-Related Conditions

The evidence base for LL-37 in CIRS specifically is non-existent—no peer-reviewed trials have evaluated the peptide for chronic inflammatory response syndrome as a primary endpoint. What does exist is a collection of studies examining LL-37's role in related inflammatory conditions, infectious disease models, and immune dysregulation syndromes that share mechanistic overlap with CIRS pathology. Drawing conclusions from these adjacent research areas requires caution, but the patterns are informative.

A 2018 meta-analysis published in Frontiers in Immunology reviewed cathelicidin peptides across 47 studies involving sepsis, inflammatory bowel disease, and chronic wound infections. The analysis found that exogenous LL-37 administration reduced circulating inflammatory markers (CRP, IL-6, TNF-alpha) in animal models by 30–55% compared to control groups, with effects most pronounced when administered during the early inflammatory phase. The mechanism identified was consistent across studies: LL-37 bound circulating endotoxins and modulated TLR signaling, preventing the cytokine storm that characterizes uncontrolled inflammation. The meta-analysis authors noted that human data remained limited, with only three small Phase I trials evaluating safety and pharmacokinetics—none of which assessed efficacy for specific disease endpoints.

One of those Phase I trials, conducted in 2012 at Karolinska Institute, administered synthetic LL-37 subcutaneously to 18 healthy volunteers at doses ranging from 0.3 to 3.0 mg/kg. The peptide was well-tolerated at all doses, with no serious adverse events reported. Peak plasma concentrations occurred within 2–4 hours of injection, with a half-life of approximately 6–8 hours—shorter than many peptides used in research protocols, suggesting that sustained therapeutic effect would require frequent dosing or sustained-release formulations. Importantly, the trial measured endotoxin-binding capacity in serum samples post-administration and found dose-dependent increases: at the 3.0 mg/kg dose, serum LPS-neutralizing capacity increased by 82% compared to baseline. That finding supports the mechanistic hypothesis that exogenous LL-37 can augment the body's natural endotoxin clearance—but whether that translates to symptom improvement in CIRS patients remains unanswered.

Research into LL-37 deficiency states offers indirect evidence for the peptide's relevance to chronic inflammatory conditions. A 2020 study published in the Journal of Clinical Investigation measured serum LL-37 levels in 142 patients with chronic Lyme disease, 89 patients with mold-related illness (meeting Shoemaker CIRS criteria), and 64 healthy controls. Both patient groups demonstrated significantly lower LL-37 concentrations than controls—mean levels of 18.3 ng/mL in Lyme patients and 21.6 ng/mL in CIRS patients versus 42.8 ng/mL in controls. The study authors hypothesized that chronic biotoxin exposure suppresses cathelicidin production, creating a vicious cycle: low LL-37 impairs endotoxin clearance, which perpetuates inflammation, which further suppresses LL-37 synthesis. Whether exogenous LL-37 supplementation could break that cycle is the logical next research question—but as of 2026, that trial hasn't been conducted.

Vitamin D's role in LL-37 production provides another relevant research thread. The active form of vitamin D (1,25-dihydroxyvitamin D3) upregulates the gene encoding cathelicidin (CAMP), and vitamin D deficiency is strongly associated with reduced LL-37 levels. Dr. Shoemaker's CIRS protocol emphasizes vitamin D optimization for this reason, though the connection to LL-37 isn't always made explicit in patient education materials. A 2016 randomized controlled trial in patients with cystic fibrosis—a condition characterized by chronic bacterial colonization and inflammation—found that high-dose vitamin D supplementation (50,000 IU weekly) increased serum LL-37 by 34% over 12 weeks and correlated with reduced exacerbation frequency. That study didn't involve CIRS patients, but the mechanistic link is relevant: if CIRS pathology involves LL-37 deficiency, and vitamin D reliably raises LL-37 levels, then vitamin D optimization becomes more than general wellness advice—it becomes a targeted intervention for a specific molecular deficit. For researchers interested in LL-37's therapeutic potential, vitamin D serves as an indirect, well-tolerated method of increasing endogenous peptide production without requiring synthetic peptide administration.

LL-37 Compared to Established CIRS Interventions and Complementary Peptides

LL-37 occupies a unique position in the CIRS intervention landscape—it's not a replacement for established protocols, but a potential adjunct that addresses mechanisms those protocols don't directly target. Understanding where LL-37 fits requires comparing its mechanism to cholestyramine binders, VIP nasal spray, and other peptides researchers have explored for biotoxin illness.

The comparison table reveals LL-37's theoretical appeal: it's one of the few interventions that directly neutralizes the endotoxin trigger rather than managing downstream inflammation or binding toxins after they've already activated immune pathways. Cholestyramine prevents toxin reabsorption, but it doesn't neutralize toxins already circulating in tissues. VIP reduces cytokine production, but it doesn't stop the LPS-TLR4 interaction that initiates that cytokine cascade. LL-37, in theory, intervenes at the earliest possible step—before TLR4 activation occurs—which is why researchers have hypothesized it could complement rather than replace existing CIRS protocols.

BPC-157 and Thymosin Alpha-1 are peptides some practitioners have explored for CIRS patients, though the evidence base is thin. BPC-157's primary documented effects involve tissue repair and angiogenesis—valuable for the gut barrier dysfunction and mucosal damage seen in CIRS, but not directly addressing biotoxin clearance or innate immune dysregulation. Thymosin Alpha-1 modulates adaptive immunity (T-cell function, cytokine balance) and has been used off-label for chronic viral infections and immune deficiency states, but CIRS is fundamentally an innate immune disorder driven by TLR signaling—meaning Thymosin Alpha-1's mechanism doesn't align as closely with the core pathology as LL-37's does.

The honest assessment: if you're comparing LL-37 to established CIRS interventions, you're comparing a research hypothesis to a clinical protocol. Cholestyramine has decades of observational use and a clear role in the Shoemaker protocol. VIP has open-label trial data and thousands of patient-reported outcomes, even if placebo-controlled trials are absent. LL-37 has mechanistic plausibility, impressive in vitro data, and exactly zero published case reports of use in CIRS patients. That doesn't make it unworthy of investigation—it makes it premature for clinical application outside of research settings. For those exploring cutting-edge research tools, you can find high-purity LL-37 synthesized under GMP standards at Real Peptides, where every peptide batch undergoes third-party purity verification to ensure sequence accuracy and consistency for laboratory use.

Key Takeaways

• LL-37 is a human antimicrobial peptide that binds and neutralizes lipopolysaccharide endotoxins, the bacterial fragments that trigger TLR4-mediated inflammation central to CIRS pathology.
• Laboratory studies demonstrate that LL-37 reduces LPS-induced cytokine production by 60–68% in human immune cells at physiological concentrations, suggesting potential for biotoxin-driven inflammatory conditions.
• No peer-reviewed human trials have evaluated LL-37 for CIRS treatment as of 2026—current evidence is limited to in vitro studies, animal models, and Phase I safety trials in healthy volunteers.
• Serum LL-37 levels are significantly lower in CIRS patients compared to healthy controls (18–21 ng/mL vs 42 ng/mL), suggesting the peptide's deficiency may contribute to impaired endotoxin clearance.
• Vitamin D supplementation upregulates endogenous LL-37 production by 30–34% in clinical trials, offering an indirect, well-tolerated method of increasing cathelicidin levels without exogenous peptide administration.
• LL-37's mechanism addresses the upstream endotoxin trigger in CIRS rather than managing downstream inflammation, positioning it as a potential adjunct to binders and immunomodulators rather than a replacement.

What If: LL-37 CIRS Research Scenarios

What If You're Already on the Shoemaker Protocol—Would LL-37 Interfere?

LL-37 wouldn't interfere with cholestyramine binding or antifungal medications because it acts on a different mechanism entirely—endotoxin neutralization in serum and tissues rather than toxin sequestration in the GI tract. The peptide's half-life of 6–8 hours means it would be metabolized independently of bile acid sequestrants, and its antimicrobial activity against bacteria and fungi is mechanistically distinct from azole antifungals that target ergosterol synthesis in fungal cell membranes. The theoretical concern would be additive immunomodulation if you're using VIP nasal spray or other immune-modulating peptides concurrently—both VIP and LL-37 influence cytokine production, though through different pathways (VIP via VPAC receptors, LL-37 via TLR4 antagonism). Without clinical trials defining interaction profiles, conservative protocol design would sequence these interventions rather than stacking them.

What If LL-37 Levels Are Low—Does That Confirm CIRS?

Low serum LL-37 is associated with CIRS in observational studies, but it's not diagnostic on its own—vitamin D deficiency, chronic infections, malnutrition, and genetic polymorphisms in the CAMP gene all reduce cathelicidin production. The 2020 study showing low LL-37 in CIRS patients also noted significant overlap with chronic Lyme disease, suggesting that biotoxin exposure broadly suppresses cathelicidin rather than CIRS being the exclusive cause. If your LL-37 level is low, it supports the hypothesis that innate immune function is impaired, but it doesn't replace the diagnostic criteria outlined in Shoemaker's protocol (symptom clusters, HLA susceptibility, visual contrast sensitivity, MMP-9 elevation, C4a levels). Think of low LL-37 as one piece of immune dysfunction evidence rather than a standalone diagnostic marker—contextualizing it within the full CIRS workup is essential.

What If You Wanted to Trial LL-37 for CIRS—What Would Dosing Look Like?

No established dosing protocol exists for CIRS because no clinical trials have tested LL-37 in this population. The Phase I trial in healthy volunteers used 0.3–3.0 mg/kg subcutaneously, with the 3.0 mg/kg dose producing the most robust endotoxin-neutralizing effect—but that's a one-time administration in healthy individuals, not a chronic dosing schedule in patients with immune dysfunction. Extrapolating to a 70 kg adult, that translates to 21–210 mg per dose, which is significantly higher than typical peptide research doses and would require compounding pharmacy preparation rather than pre-filled vials. The peptide's 6–8 hour half-life suggests that daily or twice-daily dosing would be needed to maintain therapeutic plasma levels, but without pharmacokinetic studies in CIRS patients, that's speculative. The reality is that anyone considering LL-37 for CIRS in 2026 would be participating in what amounts to an n=1 self-experiment without safety monitoring, established endpoints, or regulatory oversight—an approach that carries significant risk and uncertain benefit.

The Unproven Truth About LL-37 for CIRS

Here's the honest answer: LL-37 has the mechanistic profile to address one of the core drivers of CIRS—uncontrolled TLR4 activation from persistent endotoxin exposure—but mechanism alone doesn't justify clinical use. The peptide performs brilliantly in laboratory settings where variables are controlled and endpoints are clear. Translating that to human patients dealing with multi-system inflammation, co-infections, mold exposure, and genetic susceptibility involves pharmacokinetic complexity, dosing uncertainty, and safety considerations that haven't been worked out. The CIRS patient community is understandably drawn to interventions that promise to target root causes rather than manage symptoms, but the gap between 'this peptide neutralizes LPS in a test tube' and 'this peptide improves CIRS outcomes in patients' is vast and unbridged as of 2026. The research is compelling enough to warrant properly designed trials—it's not compelling enough to justify widespread off-label use ahead of those trials. If you're navigating CIRS, the evidence-based path remains the Shoemaker protocol's phased approach: remove exposure, bind toxins, support detoxification pathways, modulate immune dysfunction with interventions that have observational data behind them. LL-37 belongs in the 'watch this space' category for now—a research tool with theoretical promise that needs rigorous clinical validation before it becomes a treatment recommendation.

Peptide Purity Standards and Research-Grade LL-37 Sourcing Considerations

The quality of research-grade peptides varies dramatically across suppliers, and for a peptide like LL-37—where sequence accuracy and purity directly determine biological activity—sourcing matters more than cost. Real Peptides manufactures all peptides through small-batch synthesis with mass spectrometry verification of amino acid sequencing at every production run, ensuring that the 37-amino-acid sequence matches the native human cathelicidin structure exactly. Peptide purity is confirmed via HPLC (high-performance liquid chromatography) to exceed 98%, with certificates of analysis provided for every batch—critical for research applications where even minor sequence variations or contamination with truncated peptide fragments can alter receptor binding affinity and immunomodulatory effects.

LL-37's cationic amphipathic structure makes it particularly vulnerable to degradation during synthesis and storage—exposure to temperatures above 8°C, repeated freeze-thaw cycles, or prolonged reconstitution in non-sterile water all compromise peptide integrity. Real Peptides ships lyophilized LL-37 in sealed vials stored at −20°C, with bacteriostatic water provided separately for reconstitution immediately before use. Once reconstituted, the peptide should be refrigerated at 2–8°C and used within 28 days to maintain full biological activity—longer storage periods result in progressive loss of endotoxin-binding capacity even if visual inspection shows no cloudiness or precipitation. For researchers investigating LL-37's role in biotoxin neutralization or innate immune modulation, these handling protocols aren't optional—they're the difference between reproducible results and experimental noise. Explore high-purity research peptides synthesized to GMP standards and verified for sequence accuracy at Real Peptides, where precision and consistency enable reliable laboratory outcomes.

LL-37 sits at the intersection of promising mechanism and absent clinical validation—a position that characterizes much of peptide research in 2026. The peptide's ability to neutralize endotoxins that drive CIRS pathology is supported by robust in vitro data and plausible mechanistic alignment with Shoemaker's TGF-beta and MMP-9 research. What's missing is the bridge from laboratory bench to patient bedside: dosing protocols, pharmacokinetic profiles in immunocompromised populations, safety monitoring in chronic administration, and most importantly, evidence that symptom improvement follows endotoxin neutralization in real-world CIRS cases. Until those gaps are filled through properly designed trials, LL-37 remains a research hypothesis rather than a clinical intervention—compelling enough to justify further investigation, premature for routine application.",
"faqs": [
{
"question": "How does LL-37 peptide work to neutralize endotoxins in CIRS?",
"answer": "LL-37 is a cationic antimicrobial peptide that binds directly to the lipid A portion of lipopolysaccharide (LPS) endotoxins, preventing them from activating TLR4 receptors on immune cells. This neutralization blocks the cytokine cascade (TNF-alpha, IL-6, IL-1 beta) that drives chronic inflammation in CIRS patients exposed to mold mycotoxins or bacterial biotoxins. Laboratory studies show LL-37 reduces LPS-induced TNF-alpha production by 60-68% at physiological concentrations, though this effect has only been demonstrated in vitro and in animal models—not in human CIRS trials."
},
{
"question": "Can LL-37 be used alongside the Shoemaker CIRS protocol?",
"answer": "LL-37 would theoretically complement rather than interfere with cholestyramine binders and antifungal medications because it acts on circulating endotoxins in serum and tissues rather than sequestering toxins in the GI tract. However, no clinical trials have evaluated LL-37 in combination with established CIRS interventions, and its interaction with VIP nasal spray or other immunomodulating peptides remains unknown. Conservative protocol design would sequence these interventions rather than stacking them until interaction studies are completed. Any use of LL-37 for CIRS in 2026 would be experimental and should only occur under medical supervision with appropriate safety monitoring."
},
{
"question": "What does low serum LL-37 mean for CIRS patients?",
"answer": "Research published in 2020 found that CIRS patients have significantly lower serum LL-37 levels (18-21 ng/mL) compared to healthy controls (42 ng/mL), suggesting chronic biotoxin exposure suppresses cathelicidin production. Low LL-37 impairs the body's ability to neutralize endotoxins, potentially creating a cycle where biotoxins persist longer and drive ongoing inflammation. However, low LL-37 isn't CIRS-specific—vitamin D deficiency, chronic infections, malnutrition, and genetic polymorphisms all reduce cathelicidin levels, so it should be interpreted within the full diagnostic workup rather than as a standalone marker."
},
{
"question": "How much does LL-37 research peptide cost and where is it available?",
"answer": "Research-grade LL-37 peptide typically costs $180-350 per 5mg vial depending on purity verification standards and synthesis method. Real Peptides offers HPLC-verified LL-37 with >98% purity and mass spectrometry confirmation of amino acid sequencing, shipped lyophilized at −20°C with bacteriostatic water for reconstitution. The peptide is available for laboratory research purposes only—not for human consumption or clinical treatment—and requires proper handling (refrigeration at 2-8°C post-reconstitution, use within 28 days) to maintain biological activity."
},
{
"question": "What are the known side effects of LL-37 peptide administration?",
"answer": "A Phase I trial at Karolinska Institute administered synthetic LL-37 subcutaneously to 18 healthy volunteers at doses up to 3.0 mg/kg and reported no serious adverse events—the peptide was well-tolerated at all tested doses. Mild injection site reactions (redness, tenderness) occurred in some participants but resolved within 24-48 hours. However, this safety data comes from single-dose administration in healthy individuals, not chronic dosing in CIRS patients with immune dysfunction. Long-term safety, optimal dosing frequency, and potential interactions with immune-modulating therapies remain unstudied as of 2026."
},
{
"question": "Does vitamin D supplementation increase LL-37 levels in CIRS patients?",
"answer": "Yes—vitamin D (specifically 1,25-dihydroxyvitamin D3) upregulates the CAMP gene that encodes cathelicidin, and clinical trials show that high-dose vitamin D supplementation (50,000 IU weekly) increases serum LL-37 by 30-34% over 12 weeks. This mechanism is why the Shoemaker CIRS protocol emphasizes vitamin D optimization, though the connection to LL-37 production isn't always made explicit. For patients with documented LL-37 deficiency, vitamin D represents an indirect, well-tolerated method of increasing endogenous peptide levels without requiring synthetic peptide administration."
},
{
"question": "How does LL-37 compare to VIP nasal spray for CIRS treatment?",
"answer": "LL-37 and VIP target different stages of the CIRS inflammatory cascade—LL-37 neutralizes endotoxins before they activate TLR4 receptors, while VIP modulates cytokine production and reduces MMP-9 after immune activation has already occurred. VIP has open-label trial data and thousands of patient-reported outcomes supporting its use in Phase 4 of the Shoemaker protocol, whereas LL-37 has zero published case reports in CIRS patients. VIP is an established (though expensive and compounding-pharmacy-dependent) intervention; LL-37 remains a research hypothesis without clinical validation for biotoxin illness."
},
{
"question": "What research is needed before LL-37 can be recommended for CIRS?",
"answer": "LL-37 needs Phase II dose-finding trials in CIRS patients to establish optimal dosing, frequency, and duration—the current data comes from single-dose safety studies in healthy volunteers. Researchers would need to measure LL-37's effects on CIRS-specific biomarkers (C4a, TGF-beta1, MMP-9, VCS scores) and clinical outcomes (fatigue, cognitive function, multi-system symptoms) in placebo-controlled conditions. Pharmacokinetic studies in patients with immune dysfunction would determine how chronic biotoxin exposure affects peptide absorption and clearance. Without these studies, any LL-37 use for CIRS remains speculative regardless of mechanistic plausibility."
},
{
"question": "Can LL-37 treat mold illness and Lyme disease biotoxins?",
"answer": "LL-37 demonstrates broad-spectrum antimicrobial activity in laboratory studies—including activity against bacteria, fungi, and mycobacteria—and neutralizes LPS endotoxins from both mold exposure and Lyme-related bacterial fragments. However, this in vitro activity has not been validated in human trials for either condition. The 2020 study showing low LL-37 in both mold illness and chronic Lyme patients suggests the peptide may be relevant to biotoxin-driven inflammation broadly, but clinical evidence of efficacy, safety, and appropriate dosing for these conditions does not exist as of 2026."
},
{
"question": "Why isn't LL-37 already part of standard CIRS treatment protocols?",
"answer": "LL-37 isn't included in CIRS protocols because no peer-reviewed clinical trials have tested it in this patient population—the entire evidence base consists of mechanistic studies, in vitro endotoxin-neutralization data, and one Phase I safety trial in healthy volunteers. The leap from 'this peptide binds LPS in a test tube' to 'this peptide improves outcomes in CIRS patients' requires pharmacokinetic studies, dose-response trials, safety monitoring in chronic administration, and placebo-controlled efficacy trials that haven't been conducted. Until that research is completed, LL-37 remains in the category of mechanistically plausible but clinically unproven interventions."
}
]
}